p53 and chemosensitivity

Annals of Oncology

Volumn 10, Issue 9, 1999, Pages 1011-1021

  Ferreira, C G ^a   Tolis, C ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Chemosensitivity; Cytotoxicity; p53

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; PROTEIN P53;

APOPTOSIS; BREAST CARCINOMA; CANCER RESISTANCE; CELL CYCLE; CELL SURVIVAL; CHROMOSOME 17P; CYTOTOXICITY; DNA REPAIR; GASTROINTESTINAL CARCINOMA; GENE MUTATION; HUMAN; LUNG CARCINOMA; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032822891     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008361818480     Document Type: Review

References (113)

1. Cote RJ, Esrig D, Groshen S et al. p53 and treatment of bladder cancer (Letter; comment). Nature 1997; 385: 123-5.
2. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
3. Lane DP. p53 and human cancers. Br Med Bull 1994; 50: 582-99.
4. Resnick-Silverman L, St. Clair S, Maurer M et al. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 1998; 12: 2102-7.
5. Di Leonardo A, Linke SP, Clarkin K et al. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-51.
6. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 1997; 57: 1171-9.
7. Morgan SE, Kastan MB. p53 and ATM: Cell cycle, cell death, and cancer. Adv Cancer Res 1997; 71: 1-25.
8. Westphal CH, Schmaltz C, Rowan S et al. Genetic interactions between ATM and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res 1997; 57: 1664-7.
9. Banin S, Moyal L, Shieh S et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Gastroenterology 1998; 281: 1674-7.
10. Watters D, Khanna KK, Beamish H et al. Cellular localisation of the ataxia-telagiectasia gene product (ATM) and discrimination between mutated and normal forms. Oncogene 1997; 14 (16): 1911-21.
11. Canman CE, Lim DS, Cimprich KA et al. Activaton of ATM kinase by ionizing irradiation and phosphorylation of p53. Science 1998; 281 (5383): 1677-9.
12. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998; 16: 311-20.
13. Shivakumar CV, Brown DR, Deb S et al. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1995; 15: 6785-93.
14. Matsuzawa S, Takayama S, Froesch BA et al. p53-inducible human homologue of Drosophila seven in absensia (Siah) inhibits cell growth: Supression by BAG-1. EMBO J 1998; 17 (10): 2736-47.
15. Stewart N, Hicks GG, Paraskevas F et al. Evidence for a second cell cycle block at G2/M by p53. Oncogene 1995; 10: 109-15.
16. Agarwal ML, Agarwal A, Taylor WR et al. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8493-7.
17. Kulesz-Martin MF, Lisafeld B, Huang H et al. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol 1994; 14: 1698-708.
18. Li Y, Jenkins CW, Nichols MA et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994; 9: 2261-8.
19. Niculescu AB, Chen X, Smeets M et al. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication [published erratum appears in Mol Cell Biol 1998; 18 (3): 1763]. Mol Cell Biol 1998; 18: 629-43.
20. Niculescu AB, Chen X, Smeets M et al. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication [published erratum appears in Mol Cell Biol 1998; 18 (3): 1763]. Mol Cell Biol 1998; 18: 629-43.
21. Hermeking H, Lengauer C, Polyak K et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
22. Johnson P, Chung S, Benchimol S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol 1993; 13: 1456-63.
23. Li CY, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995; 270: 4971-4.
24. Qiu X, Forman HJ, Schonthal AH et al. Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells. J Biol Chem 1996; 271: 31915-21.
25. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxy-vitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996; 58: 395-401.
26. van Billon N, Grunsven LA, Rudkin BB. The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. Oncogene 1996; 13: 2047-54.
27. Nadal A, Jares P, Cazorla M et al. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 1997; 183: 156-63.
28. Smith ML, Chen IT, Zhan Q et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Gastroenterology 1994; 266: 1376-80.
29. Attardi LD, Lowe SW, Brugarolas J et al. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 1996; 15: 3693-701.
30. Steller H. Mechanisms and genes of cellular suicide. Gastroenterology 1995; 267: 1445-9.
31. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 1996; 15: 1596-606.
32. Caelles C, Heimberg A, Karin M. p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-3.
33. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
34. Miyashita T, Harigai M, Hanada M et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-5.
35. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
36. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis [published erratum appears in Mol Cell Biol 1994; 14 (6): 4333]. Mol Cell Biol 1994; 14: 2556-63.
37. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis [published erratum appears in Mol Cell Biol 1994; 14 (6): 4333]. Mol Cell Biol 1994; 14: 2556-63.
38. Polyak K, Xia Y, Zweier JL et al. A model for p53-induced apoptosis. Nature 1997; 389: 300-5.
39. Owen-Schaub LB, Zhang W, Cusack JC et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-40.
40. Bennett M, Macdonald K, Chan SW et al. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 1998; 282 (5387): 290-3.
41. Mietz JA, Unger T, Huibregtse JM et al. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992; 11: 5013-20.
42. Maxwell SA, Roth JA. Posttranslational regulation of p53 tumor suppressor protein function. Crit Rev Oncog 1994; 5: 23-57.
43. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 1993; 7: 535-45.
44. Demers GW, Halbert CL, Galloway DA. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 1994; 198: 169-74.
45. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992; 357: 82-5.
46. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Gastroenterology 1990; 248: 76-9.
47. Scheffner M, Werness BA, Huibregtse JM et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
48. Bottger A, Bottger V, Sparks A et al. Design of a synthetic Mdm-2 binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7 (11): 860-9.
49. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Gastroenterology 1991; 253: 49-53.
50. Casey G, Lopez ME, Ramos JC et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13: 1971-81.
51. Iggo R, Gatter K, Bartek J et al. Increased expression of mutant forms ofp53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
52. Unger T, Nau MM, Segal S et al. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992; 11: 1383-90.
53. Fan S, el-Deiry WS, Bae I et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994 54 (22): 5824-30.
54. Fan S, Smith ML, Rivet DJ et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55 (8): 1649-54.
55. Brachman DG, Beckett M, Graves D et al. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993; 53: 3667-9.
56. Thottassery JV, Zambetti GP, Arimori K et al. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997; 94(20): 11037-42.
57. Strauss BE, Shivakumar C, Deb SP et al. The MDR1 down-stream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 1995; 217: 825-31.
58. Li ZH, Zhu YJ, Lit XT et al. Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Lett 1997; 119: 177-84.
59. Zastawny RL, Salvino R, Chen J et al. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993; 8: 1529-35.
60. Lowe SW, Ruley HE, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74 (6): 957-67.
61. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
62. Ju JF, Banerjee D, Lenz HJ et al. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 1998; 4 (5): 1315-22.
63. Yang B, Eshleman JR, Berger NA et al. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 1649-57.
64. Weinstein JN, Myers TG, O'Connor PM et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275 (5298): 343-9.
65. O'Connor PM, Jackman J, Bae I et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300.
66. Vasey PA, Jones NA, Jenkins S et al. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996; 50 (6): 1536-40.
67. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56 (4): 892-8.
68. Vikhanskaya F, D'Incalci M, Broggini M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer 1995; 61 (3): 397-401.
69. Trepel M, Scheding S, Groscurth P et al. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia 1997; 11 (11): 1842-99.
70. Debernardis D, De Sire EG, Feudis P et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57 (5): 870-4.
71. Fan S, Cherney B, Reinhold W et al. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin Cancer Res 1998; 4 (4): 1047-54.
72. Wu GS, El-Diery WS. p53 and chemosensitivity [Letter]. Nature Med 1996; 2(3): 255-6.
73. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2(1): 72-9.
74. Cross SM, Sanchez CA, Morgan CA et al. A p53-dependent mouse spindle checkpoint. Gastroenterology 1995; 267: 1353-6.
75. Rosell R, Gonzalez-Larriba JL, Alberola V et al. Single-agent paclitaxel by three-hour infusion in the treatment of non-small-cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995; 22 (6, Suppl 14): 12-8.
76. Rusch V, Klimstra D, Venkatraman E et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small-cell lung cancer. Cancer Res 1995; 55 (21): 5038-42.
77. Stal O, Stenmark AM, Wingren S et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995; 34: 767-70.
78. Olivotto IA, Bajdik CD, Plenderleith IH et al. Adjuvant systemic therapy and survival after breast cancer (see comments). N Engl J Med 1994; 330 (12): 805-10.
79. Coles C, Condie A, Chetty U et al. p53 mutations in breast cancer. Cancer Res 1992; 52 (19): 5291-8.
80. Aas T, Borresen AL, Geisler S et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-4.
81. Bergh J, Norberg T, Sjogren S et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1: 1029-34.
82. Clahsen PC, van de Velde CJ, Duval C et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: 470-9.
83. Makris A, Powles TJ, Dowsett M et al. p53 protein overexpression and chemosensitivity in breast cancer (Letter; comment). Lancet 1995; 345 (8958): 1181-2.
84. Linn SC, Pinedo HM, van Ark-Otte J et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997; 71: 787-95.
85. Jacquemier J, Penault-Llorca F, Viens P et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 1994; 14: 2773-8.
86. de Degeorges A, Roquancourt A, Extra JM et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 1998; 47: 47-55.
87. Elledge RM, Gray R, Mansour E et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995; 87: 1254-6.
88. Smith-Sorensen B, Kaern J, Holm R et al. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to Tp53 gene status. Br J Cancer 1998; 78 (3): 375-81.
89. Marks JR, Davidoff AM, Kerns BJ et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51 (11): 2979-84.
90. Buttitta F, Marchetti A, Gadducci A et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study. Br J Cancer 1997; 75 (2): 230-5.
91. Righetti SC, Della, Torre G, Pilotti S et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56 (4): 689-93.
92. Renninson J, Baker BW, McGown AT et al. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: Correlation with histopathology and clinical features. Br J Cancer 1994; 69 (3): 609-12.
93. Di Leo A, Bajetta E, Biganzoli L et al. An ITMO group study on second-line treatment in advanced epithelial ovarian cancer: An attempt to identify clinical and biological factors determining prognosis. Eur J Cancer 1995; 31A (13-14): 2248-54.
94. Kawasaki M, Nakanishi Y, Kuwano K et al. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer. p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small-cell lung cancer. Clin Cancer Res 1997; 3: 1195-200.
95. Kobayashi H, Tanisaka K, Kondo N et al. Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness. Jap J Cancer Chemother 1995; 22 (13): 1933-9.
96. Higashiyama M, Kodama K, Yokouchi H et al. Immunohistochemical p53 protein status in non-small-cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol 1998; 68 (1): 19-24.
97. Brett MC, Pickard M, Green B et al. p53 protein overexpression and response to hiomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Sur Oncol 1996; 22 (2): 182-5.
98. Lenz HJ, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998; 4 (5): 1243-50.
99. Paradiso A, Rabinovich M, Vallejo C et al. p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis. Int J Cancer 1996; 69 (6): 437-41.
100. Boku N, Chin K, Hosokawa K et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998; 4 (6): 1469-74.
101. Iwadate Y, Fujimoto S, Tagawa M et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996; 69 (3): 236-40.
102. Goto A, Kanda H, Ishikawa Y et al. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jap J Cancer Res 1998; 89 (5): 539-47.
103. Eid H, Van der Looij M, Institoris E et al. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res 1997; 17 (4A): 2663-9.
104. Schenkman NS, Sesterhenn IA, Washington L et al. Increased p53 protein does not correlate to p53 gene mutations in micro-dissected human testicular germ cell tumors. J Urol 1995; 154 (2 Pt 1): 617-21.
105. Apolinario RM, van der Valk P, de Jong JS et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15 (6): 2456-66.
106. Yusuf S, Wittes J, Probstfield J et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266(1): 93-8.
107. Fujiwara T, Cai DW, Georges RN et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst; 86 (19): 1458-62.
108. Nguyen DM, Spitz FR, Yen N et al. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiov Surg 1996; 112 (5): 1372-6.
109. Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-91.
110. Clayman GL, el-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-32.
111. Bouvet M, Ellis LM, Nishizaki M et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288-92.
112. Cai DW, Mukhopadhyay T, Liu Y et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993; 4: 617-24.
113. Selivanova G, Iotsova V, Okan I et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 1997; 3: 632-8.